Northbaze Group - 2021 Outlook
2021-02-24 08:20:00
Redeye raises its base case valuation of Northbaze on the back of a strong year-end report with 50% y/y growth, accompanied by an 8% EBITDA margin. We argue that the new level of stability in the business following four profitable quarters, together with a good outlook for growth, merits an increased base case valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/